HUP0401582A2 - Nem-szteroid gyulladásgátlók és PDE4 inhibitorok kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Nem-szteroid gyulladásgátlók és PDE4 inhibitorok kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0401582A2
HUP0401582A2 HU0401582A HUP0401582A HUP0401582A2 HU P0401582 A2 HUP0401582 A2 HU P0401582A2 HU 0401582 A HU0401582 A HU 0401582A HU P0401582 A HUP0401582 A HU P0401582A HU P0401582 A2 HUP0401582 A2 HU P0401582A2
Authority
HU
Hungary
Prior art keywords
inhibitors
pde
nsaid
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0401582A
Other languages
English (en)
Inventor
Thomas Klein
Hans-Peter Kley
Armin Hatzelmann
Manfrid Eltze
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of HUP0401582A2 publication Critical patent/HUP0401582A2/hu
Publication of HUP0401582A3 publication Critical patent/HUP0401582A3/hu
Publication of HU229442B1 publication Critical patent/HU229442B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány PDE4-inhibitorok és nemszteroid gyulladásgátlók kombináltadagolása gyulladásos betegségekkel és/vagy gyulladással társultrendellenességek kezelésére, a nem-szteroid gyulladásgátlókfelhasználásával gyakran társult gyomor-bélrendszeri mellékhatások(pl: gasztrikus eróziók és fekély) minimalizálása mellett. Ó
HU0401582A 2001-09-19 2002-09-17 Nem-szteroid gyulladásgátlók és PDE4 inhibitorok kombinációi és alkalmazásuk HU229442B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19
PCT/EP2002/010424 WO2003024489A2 (en) 2001-09-19 2002-09-17 Combination of a nsaid and a pde-4 inhibitor

Publications (3)

Publication Number Publication Date
HUP0401582A2 true HUP0401582A2 (hu) 2004-11-29
HUP0401582A3 HUP0401582A3 (en) 2008-04-28
HU229442B1 HU229442B1 (hu) 2013-12-30

Family

ID=8176065

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401582A HU229442B1 (hu) 2001-09-19 2002-09-17 Nem-szteroid gyulladásgátlók és PDE4 inhibitorok kombinációi és alkalmazásuk

Country Status (25)

Country Link
US (2) US20040242597A1 (hu)
EP (1) EP1429807B1 (hu)
JP (1) JP4588998B2 (hu)
KR (1) KR100949528B1 (hu)
CN (1) CN100496607C (hu)
AT (1) ATE355080T1 (hu)
AU (1) AU2002337105B2 (hu)
BR (1) BR0212606A (hu)
CA (1) CA2459757C (hu)
CY (1) CY1108011T1 (hu)
DE (1) DE60218497T2 (hu)
DK (1) DK1429807T3 (hu)
EA (1) EA008108B1 (hu)
ES (1) ES2282469T3 (hu)
HK (1) HK1066730A1 (hu)
HU (1) HU229442B1 (hu)
IL (2) IL160271A0 (hu)
MX (1) MXPA04002562A (hu)
NO (1) NO331756B1 (hu)
NZ (1) NZ532278A (hu)
PL (1) PL210463B1 (hu)
PT (1) PT1429807E (hu)
SI (1) SI1429807T1 (hu)
WO (1) WO2003024489A2 (hu)
ZA (1) ZA200402654B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (en) * 2003-05-28 2004-12-23 Glaxo Group Limited Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
US20050059741A1 (en) * 2003-08-07 2005-03-17 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
BRPI0415753A (pt) * 2003-10-21 2006-12-19 Pharmacia Corp método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
WO2006097459A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
WO2006134022A1 (en) * 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Mrp iv inhibitors for the treatment of respiratory diseases
EP2012763B1 (en) * 2006-04-28 2011-03-23 Grünenthal GmbH Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
BRPI0906809A2 (pt) 2008-01-25 2015-07-14 High Point Pharmaceuticals Llc Compostos tricíclicos como moduladores da síntese do tnf-(alfa) e como inibidores da pde4.
JP5745861B2 (ja) * 2008-03-04 2015-07-08 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 炎症性疼痛を治療する方法
EP2400962B1 (de) * 2009-02-27 2017-11-08 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
EP2400961B1 (de) * 2009-02-27 2017-11-22 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4069213A1 (en) * 2019-12-03 2022-10-12 The USA, as represented by The Secretary, Department of Health and Human Services Cyclooxygenase-2 inhibition for the treatment of saa-high asthma
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IL311534A (en) * 2021-09-22 2024-05-01 Iolyx Therapeutics Inc Methods for treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
EP1028946A1 (en) 1997-11-04 2000-08-23 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
JP2003503360A (ja) 1999-06-24 2003-01-28 ファルマシア コーポレイション 炎症性疾患の処置のための併用療法
CA2381802C (en) * 1999-08-21 2010-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of roflumilast and salmeterol
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AR029189A1 (es) * 1999-11-02 2003-06-18 Smithkline Beecham Corp Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
AU2700201A (en) * 2000-01-31 2001-08-14 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
PL356447A1 (en) * 2000-02-08 2004-06-28 Smithkline Beecham Corporation Method and compositions for treating an inflammatory disease
PL364910A1 (en) * 2001-01-31 2004-12-27 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
EE05386B1 (et) * 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim

Also Published As

Publication number Publication date
WO2003024489A3 (en) 2003-09-18
NO20041596L (no) 2004-06-18
HU229442B1 (hu) 2013-12-30
JP2005504077A (ja) 2005-02-10
ZA200402654B (en) 2005-04-26
DE60218497T2 (de) 2007-11-08
KR100949528B1 (ko) 2010-03-25
US8242146B2 (en) 2012-08-14
KR20040053129A (ko) 2004-06-23
HK1066730A1 (en) 2005-04-01
WO2003024489A2 (en) 2003-03-27
PL369472A1 (en) 2005-04-18
PL210463B1 (pl) 2012-01-31
HUP0401582A3 (en) 2008-04-28
SI1429807T1 (sl) 2007-08-31
EA008108B1 (ru) 2007-04-27
DK1429807T3 (da) 2007-06-18
MXPA04002562A (es) 2004-05-31
JP4588998B2 (ja) 2010-12-01
AU2002337105B2 (en) 2008-03-20
EP1429807A2 (en) 2004-06-23
US20040242597A1 (en) 2004-12-02
CA2459757A1 (en) 2003-03-27
DE60218497D1 (de) 2007-04-12
IL160271A (en) 2008-03-20
CN100496607C (zh) 2009-06-10
IL160271A0 (en) 2004-07-25
ATE355080T1 (de) 2006-03-15
CY1108011T1 (el) 2013-09-04
PT1429807E (pt) 2007-05-31
NO331756B1 (no) 2012-03-19
ES2282469T3 (es) 2007-10-16
EA200400410A1 (ru) 2004-12-30
US20080255209A1 (en) 2008-10-16
EP1429807B1 (en) 2007-02-28
CA2459757C (en) 2011-08-30
NZ532278A (en) 2006-02-24
BR0212606A (pt) 2004-08-17
CN1625411A (zh) 2005-06-08

Similar Documents

Publication Publication Date Title
HUP0401582A2 (hu) Nem-szteroid gyulladásgátlók és PDE4 inhibitorok kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1411900T3 (da) Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
NO20061662L (no) Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament
DK1511481T3 (da) Ophthalmologisk anvendelse af roflumilast til behandling af øjensygdomme
BRPI0013478B8 (pt) medicamento compreendendo inibidor pde e uso de roflumilast
HUP0401998A2 (hu) PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
HUP0100867A2 (hu) Celecoxib tartalmú gyógyászati készítmények
BR0212014A (pt) Uso de derivados do ácido hidroxâmico inibidores da enzima histone deacetilase
MA31668B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
HUP0104318A2 (hu) cGMP PDE-5 inhibitort tartalmazó szabályzottan hatóanyagot felszabadító gyógyászati készítmények
HUP0202862A2 (hu) A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
WO2002085327A3 (en) Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
WO2002065977A8 (en) Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
ATE432068T1 (de) Cetirizin und pseudoephedrin enthaltende tablette
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
WO2005039483A3 (en) Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
AU2003279188A8 (en) Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
BG108144A (en) New use
HUP0401323A2 (hu) IL-18 inhibitorok alkalmazása túlérzékenységi rendellenességek esetén
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
DK1109538T3 (da) Antiinflammatoriske farmaceutiske formuleringer
DE60322577D1 (de) Tablette enthaltend efletirizin und pseudoephedrin

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: TAKEDA GMBH, DE

Free format text: FORMER OWNER(S): ALTANA PHARMA AG, DE; NYCOMED GMBH, DE

MM4A Lapse of definitive patent protection due to non-payment of fees